Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 4/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881655 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL6881661 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL25243333 | 0.72 | ALDH1A1 (0.33) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL1309656 | 0.71 | GSR (0.41) | ALDH1A1LMNAMEN1BLMKMT2A | |
| SCHEMBL2448267 | 0.71 | GSR (0.41) | ALDH1A1LMNAMEN1BLMKMT2A | |
| SCHEMBL11277663 | 0.70 | — | — | |
| SCHEMBL7106567 | 0.70 | MME (0.46) | ALDH1A1MAPTMMEACEHPGD | |
| SCHEMBL2183607 | 0.69 | KDM4E (0.34) | MAPTPTGS2MAPK1BLM | |
| SCHEMBL197221 | 0.68 | MAPT (0.50) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL80875 | 0.68 | MAPT (0.50) | ALDH1A1MAPTLMNAPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237573-B1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE OR ANGIOGENIC IMMUNOGENIC PROTEINS FOR PRODUCING SECRETORY IGA'S | NEOVACS (FR) | 2013-08-14 | — | — | EP | disclosed |
| EP-1427441-B1 | COMPOSITE SUPERIMMUNOGEN FOR BI-FUNCTIONAL VACCINE Tat-gp160 FOR USE IN THE TREATMENT OF AIDS | NEOVACS (FR) | 2010-12-01 | — | — | EP | disclosed |
| EP-1096953-B1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE AND/OR ANGIOGENIC IMMUNOGENIC PROTEINS, PREPARATION METHOD AND PHARMACEUTICAL OR VACCINE USES | NEOVACS (FR) | 2009-04-08 | — | — | EP | disclosed |
| US-7504479-B2 | Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses | NEOVACS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-7351554-B2 | Administering vaccine, native E7 protein, inactive fragment of the immunosuppressive and/or angiogenic native E7 protein;a DNA molecule encoding immunosuppressive and/or angiogenic native E7 protein inactivated by mutation; adjuvant of mucosal immunity | NEOVACS (FR) | 2008-04-01 | — | — | US | disclosed |
| US-20060153863-A1 | Administering vaccine, native E7 protein, inactive fragment of the immunosuppressive and/or angiogenic native E7 protein;a DNA molecule encoding immunosuppressive and/or angiogenic native E7 protein inactivated by mutation; adjuvant of mucosal immunity | NEOVACS (FR) | 2006-07-13 | — | — | US | disclosed |
| US-20060153862-A1 | Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses | NEOVACS (FR) | 2006-07-13 | — | — | US | disclosed |
| EP-1042363-B1 | NOVEL ANTI-HIV IMMUNOGENS (TOXOIDS), PREPARATION METHODS AND USE FOR PREVENTING AND TREATING AIDS | NEOVACS (FR) | 2006-06-21 | — | — | EP | disclosed |
| US-7022482-B2 | Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses | NEOVACS (FR) | 2006-04-04 | — | — | US | disclosed |
| US-7015016-B2 | Use of protein derived from cancer cells, cells infected by a virus or immune cells or an inactive fragment thereof, protein being initially an immunosuppressive and/or angiogenic protein for obtaining medicines to provide mucosal immunity | NEOVACS (FR) | 2006-03-21 | — | — | US | disclosed |
| US-20040001852-A1 | Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses | NEOVACS 11, RUE PERNETY (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20030003106-A1 | Use of protein derived from cancer cells, cells infected by a virus or immune cells or an inactive fragment thereof, protein being initially an immunosuppressive and/or angiogenic protein for obtaining medicines to provide mucosal immunity | NEOVACS (FR) | 2003-01-02 | — | — | US | disclosed |
| EP-1237573-A1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE OR ANGIOGENIC IMMUNOGENIC PROTEINS FOR PRODUCING SECRETORY IGA'S | NEOVACS (FR) | 2002-09-11 | — | — | EP | disclosed |
| US-6420141-B1 | PROTEIN FOR US EIN THE PREVENTION AND TREATMENT OF PREFERENTIAL VIRAL DISEASES | NEOVACS (FR) | 2002-07-16 | — | — | US | disclosed |
| WO-2001043771-A1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE OR ANGIOGENIC IMMUNOGENIC PROTEINS FOR PRODUCING SECRETORY IGA'S | NEOVACS (FR) | 2001-06-21 | — | — | WO | disclosed |
| EP-1096953-A1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE AND/OR ANGIOGENIC IMMUNOGENIC PROTEINS, PREPARATION METHOD AND PHARMACEUTICAL OR VACCINE USES | Vacs International (FR) | 2001-05-09 | — | — | EP | disclosed |
| EP-1042363-A1 | NOVEL ANTI-HIV IMMUNOGENS (TOXOIDS), PREPARATION METHODS AND USE FOR PREVENTING AND TREATING AIDS | NEOVACS (FR) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000003732-A1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE AND/OR ANGIOGENIC IMMUNOGENIC PROTEINS, PREPARATION METHOD AND PHARMACEUTICAL OR VACCINE USES | VACS INTERNATIONAL (FR) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999033872-A1 | NOVEL ANTI-HIV IMMUNOGENS (TOXOIDS), PREPARATION METHODS AND USE FOR PREVENTING AND TREATING AIDS | NEOVACS (FR) | 1999-07-08 | — | — | WO | disclosed |
| US-4847200-A | ENZYME CYCLIZATION OF DIPEPTIDES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1989-07-11 | — | — | US | disclosed |